Netherlands· NL-572e7012c9ee
Repatha 140 mg oplossing voor injectie in een voorgevulde pen
A evolocumab product containing evolocumab, registered in Netherlands by Amgen Europe B.V.. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Evolocumab is registered in 15 of 19 countries.
Countries holding a registration under ATC C10AX13 (evolocumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Evolocumab · ATC C10AX13
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of evolocumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Evolocumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$17.24
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- EVOLOCUMAB
- Manufacturer
- Amgen Europe B.V.
- Country
- Netherlands (NL)
- ATC code
- C10AX13
- ATC class
- Evolocumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/1016
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Evolocumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceREPATHA 140 mg, solution injectable en stylo prérempliAMGEN EUROPE
- IrelandRepatha 140 mg solution for injection in pre-filled penAmgen Europe B.V.
- United StatesREPATHAAmgen USA Inc.
- CzechiaREPATHAAmgen Europe B.V., Breda
- FinlandRepathaAmgen Europe B.V.
- SpainREPATHA 140 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAAmgen Europe B.V.
- IcelandRepathaAmgen Europe B.V.*
- SwedenRepatha 140 mg Injektionsvätska, lösning i förfylld injektionspennaAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Repatha
- Norway · Repatha
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/47629c00-7168-4510-956d-b729a567695b GET /v1/drugs/47629c00-7168-4510-956d-b729a567695b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/repatha-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Evolocumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp116194",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 80 (E 433)",
"PROLINE, (L-)",
"WATER VOOR INJECTIE"
],
"substances": [
"EVOLOCUMAB"
],
"leaflet_url": null,
"authorised_at": "2015/07/17",
"procedure_number": "EMEA/H/C/003766",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/1016",
"additional_monitoring": "N"
}See everything about evolocumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.